BSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,761.00
- Market cap
- ₹4,22,523 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 34.9×Sector 48.7×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Sun Pharmaceutical Industries Debt & Borrowing: ₹7,816 Cr
Sun Pharma completed allotment of ₹7,816 crore NCDs via private placement, exercising its greenshoe option of ₹816 crore. The unsecured debentures carry 8.05–8.20% coupons maturing October 2031.
- Value
- ₹7,816 Cr
- Execution
- 5 years and 1 day (26 Oct 2026 to 27 Oct 2031)
Sun Pharmaceutical Industries Business Update
Sun Pharma's drug UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines for treating locally advanced cutaneous squamous cell carcinoma.
Sun Pharmaceutical Industries Other Announcement
Sun Pharmaceutical Industries submitted the quarterly confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, as received from their RTA.
Sun Pharmaceutical Industries Credit Rating
Sun Pharma received credit ratings from CRISIL and ICRA for its proposed NCD programme and reaffirmed existing facility ratings.
Sun Pharmaceutical Industries Management Change
Sun Pharmaceutical Industries announced the resignation of Independent Director Gautam Doshi due to personal reasons.
Other credit rating announcements
All →20 Microns Credit Rating
CRISIL reaffirmed 20 Microns' bank loan ratings at A/Stable and A1 on ₹117 crore facilities. Ratings remain unchanged from prior assessment.
Epigral Credit Rating
CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.
Mankind Pharma Credit Rating
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Lloyds Metals & Energy Credit Rating
Crisil Ratings reaffirmed Lloyds Metals' bank facilities at AA/Stable and A1+, with bank limits enhanced to ₹17,112 crore. It assigned AA/Stable to ₹2,400 crore and ₹1,550 crore of NCDs.
Ram Ratna Wires Credit Rating
CARE Ratings assigned and reaffirmed Ram Ratna Wires' bank facility ratings at CARE A-; Positive / CARE A2+ and revised outlook from Stable to Positive. The long-term bank facilities total Rs.1,046.45 Crore, with several facilities enhanced.
Adani Ports & Special Economic Zone Credit Rating
Fitch Ratings affirmed Adani Ports' Long-Term Foreign-Currency IDR and unsecured notes at 'BBB-' with a Stable outlook. The affirmation keeps the existing rating unchanged.